Overview
Safety and Efficacy of AGN201781 in Neuropathic Pain
Status:
Terminated
Terminated
Trial end date:
2008-06-01
2008-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgiaPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:- Diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia
- Moderate or severe pain associated with postherpetic neuralgia or post-traumatic
peripheral neuralgia
Exclusion Criteria:
- Women of child-bearing potential
- Any other uncontrolled diseases